GlaxoSmithKline PLC ADR (GSK) revenue breakdown
By product, Respiratory is the largest at 23% of fiscal 2023 revenue; Shingles grew fastest, 42% a year over 2 years.
Revenue by product
Fiscal years, as GlaxoSmithKline PLC ADR reports them in its 10-K filings; fiscal 2023 total $30.3B.
| Products | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|
| Respiratory | $6.0B | $6.5B | $6.8B | 23% |
| HIV | $4.8B | $5.7B | $6.4B | 21% |
| Shingles | $1.7B | $3.0B | $3.4B | 11% |
| Other General Medicines | $3.6B | $3.6B | $3.4B | 11% |
| Established Vaccines | $3.0B | $3.1B | $3.3B | 11% |
| Respiratory/Immunology and Other | $2.0B | $2.6B | $3.0B | 10% |
| Meningitis | $961M | $1.1B | $1.3B | 4% |
| RSV | — | — | $1.2B | 4% |
| Oncology | $489M | $602M | $731M | 2% |
| Influenza | $679M | $714M | $504M | 2% |
| Pandemic Vaccines | $447M | $64M | $150M | 0% |
| Pandemic | $958M | $2.3B | $44M | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GSK.
Open GSK in InvestinglyQuestions
Where does GlaxoSmithKline PLC ADR make its money?
In fiscal 2023, by product: Respiratory $6.8B, HIV $6.4B, Shingles $3.4B, Other General Medicines $3.4B, Established Vaccines $3.3B.
From GlaxoSmithKline PLC ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.